Company Filing History:
Years Active: 2023
Title: Innovations in Cancer Treatment by Xiaoping Zhang
Introduction
Xiaoping Zhang is a prominent inventor based in Zürich, Switzerland. She has made significant contributions to the field of oncology, particularly in the treatment of B-cell lymphomas. Her innovative approach combines targeted therapies to improve patient outcomes.
Latest Patents
Xiaoping Zhang holds a patent for a method of treating indolent or aggressive B-cell lymphomas. The patent, titled "Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors," describes a method for preventing, delaying progression, or treating these lymphomas. The method involves administering a BTK inhibitor, specifically (S)-7-(1-acetyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody. This combination has shown a manageable toxicity profile in patients suffering from indolent and aggressive lymphomas.
Career Highlights
Xiaoping Zhang is currently associated with Beigene Switzerland GmbH, where she continues her research and development efforts in cancer therapies. Her work has been instrumental in advancing treatment options for patients with B-cell lymphomas.
Collaborations
Xiaoping collaborates with notable colleagues, including James Hilger and Shibao Feng, to further enhance the efficacy of cancer treatments. Their combined expertise contributes to the innovative approaches being developed at Beigene.
Conclusion
Xiaoping Zhang's contributions to cancer treatment through her innovative patent demonstrate her commitment to improving patient care. Her work exemplifies the impact of targeted therapies in the fight against lymphoma.